Jump to content

Kyowa Kirin

From Wikipedia, the free encyclopedia
(Redirected from Kyowa Hakko Kogyo)
Kyowa Kirin Co., Ltd.
Company typePublic (K.K)
TYO: 4151
Nikkei 225 Component
Industry
FoundedJuly 1, 1949; 75 years ago (1949-07-01)
HeadquartersOhtemachi Building, 1-6-1, Ōtemachi, Chiyoda-ku, Tokyo 100–8185, Japan
Key people
Nobuo Hanai, (CEO and President)
Products
Revenue$ 2.99 billion USD (FY 2022) Increase (¥ 398.4 billion JPY) (FY 2022)
$ 375 million USD (FY 2022) Increase (¥ 53.6 billion JPY) (FY 2022)
Number of employees
7,532 (consolidated) (as of December 31, 2017)
ParentKirin Holdings Company, Limited
Subsidiaries47 (33 in Japan and 14 overseas countries)
WebsiteOfficial website
Footnotes / references
[1][2][3]

Kyowa Kirin Co., Ltd. (協和キリン株式会社, Kyōwa Kirin Kabushiki Kaisha) is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index.[4][5]

History

[edit]

On July 1, 1949 the forerunner of the present company, Kyowa Hakko Kogyo Co., Ltd. is established. Following the merger with Kirin Pharma Co., Ltd., on October 1, 2008 the company changed its name to its present.

On July 11, 2014, the KHK subsidiary, ProStrakan Group (based in Scotland), acquired Archimedes Pharma from the Novo Nordisk Foundation for $394 million [6]

In 2019, Kirin Holdings acquired 95% stake in Kyowa Hakko Bio which is Kyowa Kirin's subsidiary corporation.[7] The entity was renamed "Kyowa Kirin Co., Ltd.", replacing its prior name of Kyowa Hakko Kirin Co., Ltd.

In November 2022, Kyowa Kirin announced plans to spin its international established medicines portfolio into a new joint venture with German company Grünenthal.[8]

In October 2023, Kyowa Kirin acquired a Britain-based biopharmaceutical company, Orchard Therapeutics, for $478 million.[9]

Business segments and products

[edit]
  • Pharmaceuticals business

The company developed a method to make afucosylated monoclonal antibodies using a CHO cell line in which FUT8 has been knocked out; the company calls this its "Potelligent" platform. The company gained marketing approval in Japan in April 2012 for a monoclonal antibody drug called mogamulizumab which was developed using the platform.[10]

References

[edit]
  1. ^ "Kyowa Hakko Kirin Company Overview". Kyowa Hakko Kirin. Retrieved March 14, 2014.
  2. ^ "Kyowa Hakko Kirin Corporate Profile" (PDF). Kyowa Hakko Kirin. Retrieved March 14, 2014.
  3. ^ "Kyowa Hakko Kirin Annual Report 2012". Kyowa Hakko Kirin. Retrieved March 14, 2014.
  4. ^ "Components:Nikkei Stock Average". Nikkei Inc. Retrieved January 20, 2015.
  5. ^ "Top 50 Pharma Companies by 2012 Revenue". Wildwood Ventures Ltd. Archived from the original on February 8, 2014. Retrieved March 14, 2014.
  6. ^ "ProStrakan Acquires Archimedes Pharma for $394M". Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. July 11, 2014. Retrieved January 20, 2015.
  7. ^ REYES, JEAN (6 February 2019). "Kirin to acquire 95% stake in Kyowa Hakko Bio".
  8. ^ "Grünenthal and Kyowa Kirin International Announce Joint Venture Collaboration for Established Medicines Portfolio". www.businesswire.com. 2022-11-24. Retrieved 2022-11-29.
  9. ^ "Kyowa Kirin to acquire Orchard Therapeutics for $478 million". Reuters. 2023-10-05. Retrieved 2023-10-05.
  10. ^ Yu, X; Marshall, MJE; Cragg, MS; Crispin, M (June 2017). "Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering" (PDF). BioDrugs. 31 (3): 151–166. doi:10.1007/s40259-017-0223-8. PMID 28466278. S2CID 3722081.
  11. ^ "FY 2013 Consolidated Financial Summary". Kyowa Hakko Kirin. Archived from the original on March 4, 2016. Retrieved March 14, 2014.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Kyowa_Kirin&oldid=1242608255"